| 51 |
35608822 | Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. | 2022 May 24 |
1 |
| 52 |
35628931 | Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. | 2022 May 16 |
1 |
| 53 |
31949019 | Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. | 2021 Jan 1 |
1 |
| 54 |
32336682 | Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia. | 2021 Mar 1 |
1 |
| 55 |
32640487 | BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. | 2021 Jan |
1 |
| 56 |
32683672 | Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. | 2021 Jan 15 |
3 |
| 57 |
32855274 | Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines. | 2021 Oct 1 |
1 |
| 58 |
32961571 | Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. | 2021 Feb |
1 |
| 59 |
32978866 | Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course. | 2021 Feb |
1 |
| 60 |
32979005 | Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair. | 2021 Jan 5 |
3 |
| 61 |
33011863 | ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. | 2021 Apr |
1 |
| 62 |
33171493 | miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. | 2021 May 6 |
1 |
| 63 |
33190294 | Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. | 2021 Mar |
2 |
| 64 |
33216986 | Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. | 2021 Apr |
3 |
| 65 |
33272709 | Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. | 2021 Jan |
1 |
| 66 |
33273263 | Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases. | 2021 Mar 1 |
1 |
| 67 |
33273682 | CXCR4 in Waldenström's Macroglobulinema: chances and challenges. | 2021 Feb |
2 |
| 68 |
33328281 | Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy. | 2021 Apr |
1 |
| 69 |
33419778 | Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. | 2021 Apr 15 |
2 |
| 70 |
33434619 | Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). | 2021 Mar |
1 |
| 71 |
33441177 | Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer. | 2021 Jan 13 |
2 |
| 72 |
33539945 | Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. | 2021 May |
1 |
| 73 |
33552659 | Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia. | 2021 Jan-Feb |
2 |
| 74 |
33567947 | Ibrutinib-induced acute kidney injury via interstitial nephritis. | 2021 Dec |
1 |
| 75 |
33570628 | Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. | 2021 Jan 12 |
1 |
| 76 |
33570649 | Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. | 2021 Jan 12 |
1 |
| 77 |
33602908 | Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. | 2021 Feb 18 |
1 |
| 78 |
33640875 | Interdisciplinary approach to the current management of chronic lymphocytic leukemia | 2021 Feb 28 |
1 |
| 79 |
33640903 | Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness. | 2021 Feb 27 |
1 |
| 80 |
33663302 | A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. | 2021 Aug |
2 |
| 81 |
33669329 | Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia. | 2021 Feb 16 |
1 |
| 82 |
33688166 | Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. | 2021 |
2 |
| 83 |
33718939 | Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. | 2021 |
2 |
| 84 |
33730585 | Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. | 2021 Mar 16 |
3 |
| 85 |
33730844 | Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. | 2021 Sep 1 |
1 |
| 86 |
33734339 | Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915. | 2021 Mar 18 |
1 |
| 87 |
33735912 | MARCKS affects cell motility and response to BTK inhibitors in CLL. | 2021 Aug 19 |
1 |
| 88 |
33740218 | Population Pharmacokinetics of Ibrutinib in Healthy Adults. | 2021 May |
1 |
| 89 |
33740548 | Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. | 2021 May 5 |
1 |
| 90 |
33754642 | Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. | 2021 Jun 24 |
1 |
| 91 |
33760219 | Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation. | 2021 May |
1 |
| 92 |
33761747 | Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry. | 2021 Apr 7 |
2 |
| 93 |
33772839 | High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. | 2021 Aug |
1 |
| 94 |
33775465 | Revisiting Richter transformation in the era of novel CLL agents. | 2021 Sep |
1 |
| 95 |
33796237 | The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. | 2021 |
2 |
| 96 |
33799484 | Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. | 2021 Mar 14 |
1 |
| 97 |
33807411 | Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells. | 2021 Mar 31 |
2 |
| 98 |
33809580 | Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. | 2021 Mar 16 |
2 |
| 99 |
33810025 | Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors. | 2021 Mar 22 |
2 |
| 100 |
33851389 | Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors. | 2021 Nov |
2 |